Valuation : H&R GmbH & Co KgaA

Market Cap 264M 306M 248M 226M 424M 28.92B 425M 2.93B 1.14B 14.84B 1.15B 1.12B 47.79B P/E 2026 *
5.48x
P/E 2027 * 19.2x
Enterprise Value 286M 333M 269M 246M 460M 31.42B 462M 3.18B 1.24B 16.12B 1.25B 1.22B 51.94B EV / Sales 2026 *
0.21x
EV / Sales 2027 * 0.2x
Free-Float
21.97%
Yield 2026 *
0.71%
Yield 2027 * 0.71%
15/08 H&R GmbH & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
16/05 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
01/04 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2025 CI
29/01 Kepler Cheuvreux Favors BASF and Bayer, Avoids H&R and Evonik DP
15/11 H&R GmbH & Co. KGaA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
14/11 H&R GmbH & Co. KGaA Revises Earnings Guidance for the Full Year 2025 CI
25/08/25 Nils Hansen acquired additional 7.78% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?15 million. CI
15/08/25 H&R GmbH & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
16/05/25 Nils Hansen proposed to acquire remaining 38.55% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?73 million. CI
14/05/25 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
17/04/25 H&R GmbH & Co. KGaA announces Annual dividend, payable on May 30, 2025 CI
09/04/25 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2024 CI
27/03/25 H&R GmbH & Co. KGaA Says Postponement Of The Publication Of The Consolidated Financial Statements And The Annual Report 2024 RE
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2016
Investor Relations Contact - 01/01/2006
Director TitleAgeSince
Chairman 62 17/04/2012
Director/Board Member 71 01/05/2011
Director/Board Member 69 01/05/2011
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 306M
-1.34%+0.38%+6.90%+25.25% 126B
+2.04%+2.27%+486.48%+236.07% 56.53B
+1.01%-0.72%-16.42%-44.45% 39.5B
+0.36%-0.49%+17.93%-19.55% 36.21B
+0.08%-0.37%+37.78%+71.11% 26.43B
-0.26%+5.12%+54.11%+366.53% 20.55B
-1.91%-0.24%+15.32%-36.27% 20.52B
-1.78%-1.17%+49.48%+15.78% 20.5B
-0.73%-3.26%+10.58%+24.97% 19.94B
Average -0.25%-0.82%+73.57%+71.05% 40.69B
Weighted average by Cap. -0.26%-1.01%+87.43%+64.31%

Financials

2026 *2027 *
Net sales 1.4B 1.62B 1.31B 1.2B 2.24B 153B 2.25B 15.52B 6.02B 78.56B 6.09B 5.96B 253B 1.36B 1.58B 1.28B 1.17B 2.19B 149B 2.2B 15.15B 5.88B 76.69B 5.94B 5.82B 247B
Net income 48.09M 55.89M 45.25M 41.33M 77.32M 5.28B 77.53M 535M 207M 2.71B 210M 205M 8.72B 13.79M 16.02M 12.97M 11.85M 22.17M 1.51B 22.23M 153M 59.49M 776M 60.17M 58.86M 2.5B
Net Debt 22.87M 26.57M 21.52M 19.65M 36.77M 2.51B 36.87M 254M 98.66M 1.29B 99.79M 97.61M 4.15B 8.65M 10.05M 8.14M 7.44M 13.91M 949M 13.95M 96.18M 37.32M 487M 37.75M 36.93M 1.57B
Logo H&R GmbH & Co KgaA
H&R GmbH & Co KGaA is a Germany-based manufacturing of chemical and pharmaceutical speciality products. The Company’s two business activities are chemicals and pharmaceutical raw materials and precision plastic parts. It operates through three segments: ChemPharm Refining, ChemPharm Sales and Plastics. The ChemPharm Refining segment, which produces oils, technical and medical white oils as well as paraffins and wax products; the ChemPharm Sales segment, which produces plasticizers and wax emulsions and the Plastics segment manufacturing precision plastic parts as well as assemblies and medical consumables.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!